Publisher Information: Linköpings universitet, Avdelningen för kardiovaskulär medicin Linköpings universitet, Medicinska fakulteten Region Östergötland, Fysiologiska kliniken US Linköpings universitet, Avdelningen för cellbiologi Region Östergötland, Klinisk genetik Western Univ, Canada; UCSF, CA USA Ohio State Univ, OH 43210 USA Hosp Sick Children, Canada; Univ Toronto, Canada Ohio State Univ, OH 43210 USA Johns Hopkins Univ, MD USA Ohio State Univ, OH 43210 USA Univ Toronto, Canada Univ British Columbia, Canada Geisinger, PA USA Ohio State Univ, OH 43210 USA Ohio State Univ, OH 43210 USA Ohio State Univ, OH 43210 USA Netherlands Heart Inst, Netherlands; Univ Groningen, Netherlands Univ Colorado Denver, CO USA Hosp Sick Children, Canada; Hosp Sick Children, Canada Hosp Sick Children, Canada; Hosp Sick Children, Canada; Univ Toronto, Canada; COMSATS Univ, Pakistan Hosp Sick Children, Canada; Univ Toronto, Canada Hosp Sick Children, Canada; Univ Toronto, Canada Hosp Sick Children, Canada; Univ Toronto, Canada Hosp Sick Children, Canada Univ Colorado Denver, CO USA; Univ Colorado Denver, CO USA Ohio State Univ, OH 43210 USA; Ohio State Univ, OH 43210 USA; Ohio State Univ, OH 43210 USA; Ohio State Univ, OH 43210 USA Ohio State Univ, OH 43210 USA; Ohio State Univ, OH 43210 USA; Ohio State Univ, OH 43210 USA; Ohio State Univ, OH 43210 USA Univ Utrecht, Netherlands Ohio State Univ, OH 43210 USA ASUITS Univ Trieste, Italy Hosp Sick Children, Canada; Univ Toronto, Canada Johns Hopkins Univ, MD USA Johns Hopkins Univ, MD USA Univ Sao Paulo, Brazil Oregon Hlth and Sci Univ, OR 97201 USA Univ Colorado, CO USA Univ Arizona, AZ USA Johns Hopkins Univ, MD USA Univ Amsterdam, Netherlands Univ Groningen, Netherlands Univ Toronto, Canada Western Univ, Canada UCSF, CA USA Western Univ, Canada Western Univ, Canada Dalhousie Univ, Canada Western Univ, Canada Univ Utrecht, Netherlands Univ Amsterdam, Netherlands McMaster Univ, Canada Ohio State Univ, OH 43210 USA Univ Colorado Denver, CO USA Univ Groningen, Netherlands; Univ Amsterdam, Netherlands; UMCU, Netherlands Johns Hopkins Univ, MD USA Johns Hopkins Univ, MD USA; Med Univ South Carolina, SC 29425 USA Ohio State Univ, OH 43210 USA UCSF, CA USA Ohio State Univ, OH 43210 USA AMER SOC CLINICAL INVESTIGATION INC 2019
نبذة مختصرة : Arrhythmogenic cardiomyopathy (ACM) is an inherited arrhythmia syndrome characterized by severe structural and electrical cardiac phenotypes, including myocardial fibrofatty replacement and sudden cardiac death. Clinical management of ACM is largely palliative, owing to an absence of therapies that target its underlying pathophysiology, which stems partially from our limited insight into the condition. Following identification of deceased ACM probands possessing ANK2 rare variants and evidence of ankyrin-B loss of function on cardiac tissue analysis, an ANK2 mouse model was found to develop dramatic structural abnormalities reflective of human ACM, including biventricular dilation, reduced ejection fraction, cardiac fibrosis, and premature death. Desmosomal structure and function appeared preserved in diseased human and murine specimens in the presence of markedly abnormal beta-catenin expression and patterning, leading to identification of a previously unknown interaction between ankyrin-B and beta-catenin. A pharmacological activator of the WNT/beta-catenin pathway, SB-216763, successfully prevented and partially reversed the murine ACM phenotypes. Our findings introduce what we believe to be a new pathway for ACM, a role of ankyrin-B in cardiac structure and signaling, a molecular link between ankyrin-B and beta-catenin, and evidence for targeted activation of the WNT/beta-catenin pathway as a potential treatment for this disease.
Funding Agencies|Marianne Barrie Philanthropic Fund; Canadian Institutes of Health Research [RN332805]; Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation; Dutch Federation of University Medical Centers; Netherlands Organisation for Health Research and Development; Royal Netherlands Academy of Sciences [CVON-PREDICT 2012-10]; Netherlands Cardiovascular Research Initiative - Dutch Heart Foundation [CVON2012-10 PREDICT CVON2018-30 PREDICT2, CVON2015-12 eDETECT]; Netherlands Organization for Scientific Research (NWO) [040.11.586]; Fondation Leducq [16 CVD 02]; Dr. Francis P. Chiramonte Private Foundation; Leyla Erkan Family Fund for ARVD Research; Robin Shah ARVD Fund at Johns Hopkins; Bogle Foundation; Healing Hearts Foundation; Campanella Family; Patrick J. Harrison Family; Peter French Memorial Foundation; Wilmerding Endowments; NIH [HL135754, HL134824, HL139348, HL135096, HL114383, HL114893, HL137331, HL137325, 2UM1HG006542, UL1 TR 001079]; Ohio State Frick Center; JB Project
Processing Request
No Comments.